<DOC>
	<DOCNO>NCT00458744</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , talotrexin , work different way stop growth cancer cell , either kill cell stop dividing . PURPOSE : This phase I trial study side effect best dose talotrexin treat young patient recurrent solid tumor leukemia recurrent respond treatment .</brief_summary>
	<brief_title>Talotrexin Treating Young Patients With Recurrent Solid Tumors Leukemia That Recurrent Does Not Respond Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate maximum tolerate dose ( MTD ) recommend phase II dose talotrexin young patient recurrent solid tumor recurrent refractory leukemia . - Determine toxicity drug patient . Secondary - Determine antitumor activity drug patient . - Assess tolerability define MTD drug patient . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord diagnosis ( solid tumor v leukemia ) . - Stratum 1 ( recurrent solid tumor ) : Patients receive talotrexin IV 10 minute day 1 8 . Treatment repeat every 21 day 17 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos talotrexin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity ( DLT ) . - Stratum 2 ( recurrent refractory leukemia ) : A cohort 3-6 patient leukemia receive treatment stratum 1 MTD determine stratum 1 . If 2 3 2 6 patient experience DLT solid tumor MTD , accrual stop . After completion study treatment , patient follow 30 day . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis either following : Recurrent solid tumor Histologically confirmed* malignancy original diagnosis relapse Measurable evaluable disease Lymphoma primary CNS tumor allow Patients CNS tumor must stable decrease dose dexamethasone past 7 day Recurrent refractory leukemia Confirmed relapse , define M3 marrow ( 25 % blast bone marrow aspirate biopsy ) Active extramedullary disease allow provided leptomeningeal involvement NOTE : *Histological confirmation require intrinsic brain stem tumor Bone marrow metastasis allow Not refractory red blood cell platelet transfusion No pleural effusion significant ascites No known curative therapy therapy proven prolong survival acceptable quality life exist No Down syndrome PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 50100 % ( patient &gt; 10 year age ) OR Lansky PS 50100 % ( patient ≤ 10 year age ) Absolute neutrophil count ≥ 1,000/mm³ ( patient solid tumor without bone marrow involvement ) Platelet count ≥ 100,000/mm³ ( transfusion independent ) Hemoglobin ≥ 8.0 g/dL Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine adjust accord age follow : No great 0.6 mg/dL ( 1 year 23 month ) No great 0.8 mg/dL ( 2 5 year ) No great 1.0 mg/dL ( 6 9 year ) No great 1.2 mg/dL ( 10 12 year ) No great 1.4 mg/dL ( 13 year [ female ] ) No great 1.5 mg/dL ( 13 15 year [ male ] ) No great 1.7 mg/dL ( 16 year [ male ] ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 110 U/L ( ULN 45 U/L ) Albumin ≥ 2 g/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection No known condition , opinion investigator , would preclude study compliance PRIOR CONCURRENT THERAPY : Recovered prior treatmentrelated toxicity At least 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosourea ) ( patient solid tumor ) At least 24 hour since prior cytoreduction therapy initiate hydroxyurea ( patient leukemia ) At least 2 week since prior local palliative radiotherapy ( small port ) At least 6 month since prior totalbody irradiation ( TBI ) , craniospinal radiotherapy , ≥ 50 % radiotherapy pelvis At least 6 week since prior substantial bone marrow radiotherapy At least 3 month since prior stem cell transplant rescue without TBI No evidence active graftversushost disease At least 7 day since prior growth factor therapy At least 7 day since prior biological therapy No nonsteroidal antiinflammatory drug ( NSAIDs ) , aspirin salicylate , penicillin , sulfa drug ( bactrim , septra ) , ciprofloxacin , tetracycline , thiazide diuretic , probenecid within 2 day prior , , within 5 day treatment talotrexin No longacting NSAIDs ( e.g. , nabumetone , naproxen , oxaprozin , piroxicam ) within 5 day prior , , within 5 day treatment talotrexin No concurrent investigational drug No concurrent anticancer agent therapy ( e.g. , chemotherapy , radiotherapy , immunotherapy , biologic therapy )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent childhood visual pathway glioma</keyword>
	<keyword>high-grade childhood cerebral astrocytoma</keyword>
	<keyword>low-grade childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>childhood spinal cord tumor</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood pineoblastoma</keyword>
</DOC>